When it comes to matching the commercial scale-up to the innovations taking place across Kite’s pipeline, Alquist admitted ...

Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...

Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher (PRV), striking a $180 ...

GSK’s Tesaro unit took a blow in its legal feud with Jemperli developer AnaptysBio, with a Delaware court dismissing GSK’s ...

Haleon has kicked off a soccer-focused marketing campaign ahead of the Fifa World Cup coming to the U.S., putting midfielder ...

After breaking through the blockbuster sales threshold in 2025, AstraZeneca’s three-in-one inhaler Breztri Aerosphere has ...

Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as the company has ...

Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition (PDF) ...

After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

The FDA has taken umbrage with certain Incyte promotional claims related to its chronic graft-versus-host disease (cGVHD) ...

Mundipharma and CorMedix have unveiled a win for their antifungal drug Rezzayo at preventing invasive fungal diseases in ...